Werewolf Therapeutics, Inc. current report, 21 June 2023

Full document

Werewolf Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

Werewolf Therapeutics, Inc. filed a Form 8-K reporting events occurring on June 21, 2023, including amendments to its bylaws and results of its annual meeting of stockholders. The report was signed on June 27, 2023. The company’s common stock trades on Nasdaq under the symbol HOWL.

Key Financial Metrics

This filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, cash balance, or other operating financial metrics.

Material Changes and Corporate Governance

  • The board adopted Second Amended and Restated Bylaws, effective June 21, 2023.
  • The amendments revise procedures for stockholder meeting notices, voting-list requirements, adjournments, and advance notice requirements for director nominations and stockholder proposals.
  • The bylaws require nominating stockholders directly or indirectly soliciting proxies to use a proxy card color other than white.
  • The amendments incorporate changes relating to Delaware General Corporation Law provisions and Rule 14a-19 universal proxy requirements.
  • The prior provision addressing director compensation was removed, along with technical and conforming revisions.

Annual Meeting Results, Outlook, and Risks

  • Meeta Chatterjee, Ph.D., Derek DiRocco, Ph.D., and Daniel J. Hicklin, Ph.D. were elected as Class II directors for three-year terms ending at the 2026 annual meeting.
  • Votes for, withheld, and broker non-votes were respectively 18,766,485, 4,810,351, and 6,323,280 for Ms. Chatterjee; 18,471,357, 5,105,479, and 6,323,280 for Dr. DiRocco; and 23,547,794, 29,042, and 6,323,280 for Dr. Hicklin.
  • Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 29,895,437 votes for, 3,279 against, and 1,400 abstentions.
  • The filing provides no financial guidance, operating outlook, management forecast, contingency, or unusual financial item.

Important Facts for Investors to Verify

  • Review Exhibit 3.1 for the complete amended and restated bylaws, particularly the enhanced advance-notice and proxy-solicitation requirements.
  • Assess how the amended nomination and proposal procedures may affect future stockholder actions and director elections.
  • Confirm the composition and terms of the elected Class II directors.
  • Use the company’s periodic reports, rather than this filing, to verify financial condition, cash runway, liquidity, development spending, and clinical-program outlook.